<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1727-897X</journal-id>
<journal-title><![CDATA[MediSur]]></journal-title>
<abbrev-journal-title><![CDATA[Medisur]]></abbrev-journal-title>
<issn>1727-897X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Cienfuegos, Centro Provincial de Ciencias Médicas, Provincia de Cienfuegos.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1727-897X2022000300487</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efecto analgésico de la ketamina intranasal en el tratamiento del dolor crónico oncológico]]></article-title>
<article-title xml:lang="en"><![CDATA[Analgesic effect of intranasal ketamine in the treatment of chronic cancer pain]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Pardo]]></surname>
<given-names><![CDATA[Secundino]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Longoria Boada]]></surname>
<given-names><![CDATA[Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Muñoz]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Facultad de Ciencias de la Salud. Universidad Técnica del Norte  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Facultad de Ciencias de la Salud Enrique Ortega Moreira. Universidad de Especialidades Espíritu Santo  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Facultad de Salud Pública. Universidad Camilo José Cela  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>20</volume>
<numero>3</numero>
<fpage>487</fpage>
<lpage>495</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1727-897X2022000300487&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1727-897X2022000300487&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1727-897X2022000300487&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Fundamento: el dolor por cáncer sigue siendo difícil de tratar, especialmente cuando el paciente es resistente a los opioides. Cada vez más se buscan alternativas para contrarrestar y mejorar los síntomas provocados por la enfermedad. Uno de ellos es la ketamina, que actúa como antagonista de los receptores de N-metil-daspartato que se asocian como respuesta al dolor.  Objetivo: evaluar la eficacia de la respuesta analgésica al dolor oncológico con la administración intranasal de ketamina como adyuvante en el tratamiento farmacológico.  Métodos: investigación realizada en una clínica del dolor de Ecuador. Se realizó un estudio de cohorte con placebo, aleatorizado, a doble ciego. Se incluyeron 142 participantes. Se administraron dos tratamientos: ketamina y placebo intranasal, los cuales se usaron en combinación con morfina. Los participantes recibieron evaluaciones periódicas según la escala visual analógica del dolor, durante tres días consecutivos.  Resultados:  la edad media fue de 69,11 ± 9,77 años. El carcinoma que se presentó con mayor frecuencia fue el tumor de cabeza pancreático (44,37 %). Hubo diferencias significativas entre los tratamientos administrados, los aspectos clínicos y el dolor (p &lt;0,05). Los pacientes que fueron tratados con ketamina tuvieron un efecto analgésico más relevante que los pacientes que recibieron el placebo. El principal efecto secundario fueron las náuseas (11,43 %).  Conclusiones: los pacientes tratados con ketamina experimentaron mejor analgesia que el grupo control. La ketamina representa una opción para el dolor en quien no responde al tratamiento convencional con opioides. Los efectos adversos pueden ser un limitante para su aplicación en algunos pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background: cancer pain remains difficult to treat, especially when the patient is resistant to opioids. More and more alternatives are being sought to counteract and improve the symptoms caused by the disease. One of them is ketamine, which acts as an antagonist of NMDA receptors that are associated in response to pain.  Objective: to evaluate the efficacy of the analgesic response to cancer pain with the intranasal administration of ketamine as an adjuvant in pharmacological treatment.  Methods: research carried out in Ecuador pain clinic. A randomized, double-blind, placebo-controlled cohort study was conducted. 142 participants were included. Two treatments were administered: intranasal ketamine and placebo, which were used in combination with morphine. Participants received periodic visual analog pain scale assessments for three consecutive days.  Results: the mean age was 69.11 ± 9.77 years. The pancreatic head tumor (44.37%) was the most frequently carcinoma. There were significant differences between administered treatments, clinical aspects and pain (p &lt; 0.05). The patients who were treated with ketamine had a more relevant analgesic effect than the patients who received the placebo. The main side effect was nausea (11.43%).  Conclusions: patients treated with ketamine experienced better analgesia than the control group. Ketamine represents an option for pain in those who do not respond to conventional opioid treatment. Adverse effects may limit its application in some patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[ketamina]]></kwd>
<kwd lng="es"><![CDATA[absorción nasal]]></kwd>
<kwd lng="es"><![CDATA[dolor crónico]]></kwd>
<kwd lng="es"><![CDATA[dolor en cáncer]]></kwd>
<kwd lng="en"><![CDATA[ketamine]]></kwd>
<kwd lng="en"><![CDATA[nasal absorption]]></kwd>
<kwd lng="en"><![CDATA[chronic pain]]></kwd>
<kwd lng="en"><![CDATA[cancer pain]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kroenke]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Theobald]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Loza]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carpenter]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Association of Depression and Pain with Health-Related Quality of Life, Disability, and Health Care Use in Cancer Patients]]></article-title>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>2010</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>327-41</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alese]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zakka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shaib]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A cost analysis of managing cancer-related pain among hospitalized US cancer patients]]></article-title>
<source><![CDATA[J Clinical Oncology]]></source>
<year>2020</year>
<volume>38</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>70-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Estévez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Estévez]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trastornos psicológicos en pacientes oncológicos con dolor crónico]]></article-title>
<source><![CDATA[Medicentro Electrónica]]></source>
<year>2019</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krikorian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Limonero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores asociados a la experiencia de sufrimiento en pacientes con cáncer avanzado]]></article-title>
<source><![CDATA[Avances en Psicología Latinoamericana]]></source>
<year>2015</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>423-38</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>Van Den Beuken-Van M.Hochstenbach L.Joosten A.Tjan-Heijnen V.Janssen D</collab>
<article-title xml:lang=""><![CDATA[Update on Prevalence of Pain in Patients With Cancer Systematic Review and Meta-Analysis]]></article-title>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>2016</year>
<volume>51</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1070-90</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Estilo de vida: Un enfermo de cáncer en Ecuador gasta hasta USD 17.500 en tratamiento]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Quito ]]></publisher-loc>
<publisher-name><![CDATA[Metro World News]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública del Ecuador</collab>
<source><![CDATA[Tratamiento del dolor oncológico en adultos: Guía de Práctica Clínica]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Quito ]]></publisher-loc>
<publisher-name><![CDATA[MSP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kung]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Meisner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ellis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ketamina (ketamine) revisión de un medicamento establecido pero a menudo poco reconocido]]></article-title>
<source><![CDATA[Boletín informativo APSF]]></source>
<year>2020</year>
<volume>3</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>64-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jonkman]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ketamine for cancer pain what is the evidence?]]></article-title>
<collab>van de Donk T.Dahan A</collab>
<source><![CDATA[Curr Opin Support Palliat Care]]></source>
<year>2017</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>88-92</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jové-Casulleras]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González-Barboteo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Casals-Merchán]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Porta-Sales]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pardo-Burdalo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ketamina en el tratamiento del dolor oncológico revisión de farmacocinética, farmacodinámica, interacciones medicamentosas y recomendaciones de uso]]></article-title>
<source><![CDATA[Medicina Paliativa]]></source>
<year>2010</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>241-50</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Yalcin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropathic cancer pain What we are dealing with? How to manage it?]]></article-title>
<source><![CDATA[OncoTargets and therapy]]></source>
<year>2014</year>
<volume>7</volume>
<page-range>599-618</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antagonistas de los receptores glutamatérgicos NMDA en el tratamiento del dolor crónico]]></article-title>
<source><![CDATA[Revista de la Sociedad Española del Dolor]]></source>
<year>2004</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>48-60</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Culp]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Abdi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ketamine use for cancer and chronic pain management]]></article-title>
<source><![CDATA[Frontiers in Pharmacology]]></source>
<year>2020</year>
<volume>11</volume>
<numero>599721</numero>
<issue>599721</issue>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gillespie]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intranasal Ketamine and Its Potential Role in Cancer Related Pain]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2018</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>390-401</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Buvanendran]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schwenk]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wasan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hurley]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists]]></article-title>
<source><![CDATA[Regional Anesthesia &amp; Pain Medicine]]></source>
<year>2018</year>
<volume>43</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>521-46</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La ketamina, como analgésico adyuvante para pacientes con dolor por cáncer refractario, ¿afecta la expresión de IL-2 / IFN- de las células T in vitro?: prospective, randomized, double-blind study]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2017</year>
<volume>96</volume>
<numero>16</numero>
<issue>16</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khavanin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Moezzi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Motamed]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Parozan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hosseini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intranasal Ketamine Versus Intravenous Ketorolac for Pain Control in the Renal Colic A Randomized Clinical Trial Study]]></article-title>
<source><![CDATA[Jundishapur J Chronic Dis Care]]></source>
<year>2021</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathew]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lapidus]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jarun]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ostermeyer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ketamine for treatment-resistant unipolar depression]]></article-title>
<source><![CDATA[CNS drugs]]></source>
<year>2012</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>189-204</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mercadante]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arcuri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tirelli]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Casuccio]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analgesic Effect of Intravenous Ketamine in Cancer Patients on Morphine Therapy: A Randomized, Controlled, Double-Blind, Crossover, Double-Dose Study]]></article-title>
<source><![CDATA[Journal of pain and symptom management.]]></source>
<year>2000</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>246-52</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benítez-Rosario]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Salinas-Martín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[González-Guillermo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Feria]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A strategy for conversion from subcutaneous to oral ketamine in cancer pain patients effect of a 1: 1 ratio]]></article-title>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>2011</year>
<volume>41</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1098-105</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
